Chen, L., Ahmad, N., & Liu, X. (2016). Combining p53 stabilizers with metformin induces synergistic apoptosis through regulation of energy metabolism in castration-resistant prostate cancer. Cell Cycle, 15, 840849.
Chen, L., Li, J., Farah, E., Sarkar, S., Ahmad, N., Gupta, S., . . . Liu, X. (2016). Co-targeting HSP90 and its client proteins for treatment of prostate cancer. Molecular Cancer Therapy, 15(9), 2107-2018. doi:10.1158/1535-7163.MCT-16-0241
Chen, L., Li, Z., Ahmad, N., & Liu, X. (2015). Plk1 phosphorylation of IRS2 prevents premature mitotic exit via AKT inactivation. Biochemistry, 54, 2473-2480.
Li, J., Karki, A., Hodges, K., Ahmad, N., Zoubeidi, A., Strebhardt, K., . . . Liu, X. (2015). Co-targeting Polo-like kinase 1 (Plk1) and Wnt/-catenin signaling pathway in castration-resistant prostate cancer. Mol Cell Biol, 35, 4185–4198. doi:10.1128/MCB.00825-15
Li, Z., Lu, Y., Ahmad, N., Strebhardt, K., & Liu, X. (2015). Low-dose arsenic-mediated metabolic shift is associated with activation of Polo-like kinase 1 (Plk1) Cell Cycle, 14, 3030-3039.
Shao, C., Ahmad, N., Hodges, K., Kuang, S., Ratliff, T., & Liu, X. (2015). Inhibition of Polo-like kinase 1 (Plk1) enhances the antineoplastic activity of metformin in prostate cancer. J. Biol. Chem, 290, 2024-2033. Retrieved from http://www.jbc.org/content/290/4/2024.full.pdf+html
Shao, T., & Liu, X. (2015). Identification of Rictor as a Novel Substrate of Polo-like kinase 1. Cell Cycle, 14, 755-760.
Zhang, Z., Chen, L., Wang, H., Ahmad, N., & Liu, X. (2015). Inhibition of Plk1 represses androgen signaling pathway in castration-resistant prostate cancer. Cell Cycle, 14, 2142-2148.